ReviewNature reviews. Rheumatology2018
The RA-MAP Consortium: a working model for academia-industry collaboration.
Review in Nature reviews. Rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab.PloS one · 2020Trial
- Traversing the Valley of Death for nanotechnology-based natural products: strategies and insights from pharmaceutical stakeholders.Drug delivery and translational research · 2025Article
- Unveiling research hotspots: a bibliometric study on macrophages in musculoskeletal diseases.Frontiers in immunology · 2025Review
- Designing and implementing solution-oriented team science initiatives-a chronic pain example.Frontiers in pain research (Lausanne, Switzerland) · 2025Review
- Improving the performance and interpretability on medical datasets using graphical ensemble feature selection.Bioinformatics (Oxford, England) · 2024Article
- RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients.Scientific data · 2022Article
- Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient-Companion Diagnostics.Diagnostics (Basel, Switzerland) · 2021Review
- Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study.Therapeutic advances in musculoskeletal disease · 2021Article
- The basic and translational science year in review: Confucius in the era of Big Data.Seminars in arthritis and rheumatism · 2020Review
- Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration.Nature reviews. Rheumatology · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
36 authors at 20 institutions in 10 countries.
Funding
Abstract
Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.